tbuckley/cabot-search huggingface dataset:
Safety analysis of targeted therapy in mRCC: Montenegro experience.
Authors: Vladimir Todorovic, Milan Sorat, Nevenka Lukovac Janjic
Journal: Journal of Clinical Oncology (2014)

e15560 Background: Multitargeted tyrosine kinase, VEGF and PDGFR inhibitor sunitinib is an standard of care in treatment of first line metastatic renal cell carcinoma. Clinical studies shows an important impact of optimal dosing and treatment duration on treatment outcomes. In our country from march 2012. we give sunitinib as first line treatment for patients with favourable and intermedite risk according to MSKCC. In second line we give everolimus for eligible patients. The safety profile of targeted therapy in our experience is consistant and AE are mild or moderate. Methods: We analysed patients with mRCC with hystology, confirmed metastatic disease, PS 0-2 which are treated with sunitinib as first line and everolimus in second line in the period of one year. Total number of 19 patients are evaluated with focus on side effects and management of these events. Results: According to our hospital registry we were treated 27 pts with mRCC in period of one year. In the group on sunitinib the median age is 61 year, ECOG PS 0-2, lower level of hemoglobin we find in 4 pts/16. We starts with 50 mg dose with 4+2 protocol. The duration of therapy was from 1 to 6 cycles and the dose reduction was necessary in two casses due to toxicities ( elderly pts >70 y). In the group of 16 pts on sunitinib we have PR in 7 pts and SD 8 pts. The non-hematological adverse events were: diarrhoea 7( 43 %), fatigue 7(43 %), hypertension 6 (37%) and hand and foot syndrome 5(31%). The evidence of hypothyreoidismus was found in 3 patients. Significant hematological adverse events was in two cases as trombocitopenia. The longer duration of pause was enough for normalisation of values. As second line treatment of mRCC we have 3 pts on everolimus. Treatment duration was from 4 to 6 cycles. We achive one PR and two stabile diseases. Side effects were: diarhoea 1/3, nausea 2/3, dry skin 3/3, two patients had decreased number of platelets. The symptomatic therapy and pause of treatment were enough for normalization of blood account. Conclusions: Targeted therapies for mRCC have significant efficacy. The tolerabillity of these drugs is important due to optimal dosing for achiving effective management. The prevention and managing of adverse events maximize benefit for patients with mRCC.
Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
Authors: A.S. Mansfield, R.S. Herbst, G. Castro, R. Hui, N. Peled, D.-W. Kim, S. Novello, M. Satouchi, Y.-L. Wu, E.B. Garon, M. Reck, A.G. Robinson, A. Samkari, B. Piperdi, V. Ebiana, J. Lin, T.S.K. Mok
Journal: Annals of Oncology (2019)
Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Authors: E. Garcia Torralba, D. Castellano Gauna, N. Sobrevilla, J. Guma, M.I. Luengo, J. Aparicio, A. Sanchez-Muñoz, B. Mellado, A. Saenz, C. Valverde, A. Fernández, M. Margeli, I. Duran, S. Fernandez, J. Sastre, S. Ros, P. Maroto, J.L. Aguilar, X. Garcia del Muro, E. Gonzalez Billalabeitia
Journal: Annals of Oncology (2019)
Isolated Cardiac Involvement of B-Cell Acute Lymphoblastic Leukemia Mimicking Acute Myocardial Infarction With Persistent Broad ST-Segment Elevation
Authors: YukiKakefuda, AkiraSato, TomoyaHoshi, TomokoIshizu, HiroshiTada, KaishiSatomi, YukioMorishita, YasushiOkoshi, ChihoTokunaga, YuzuruSakakibara, KazutakaAonuma
Journal: Circulation (2012)
NIMG-52. PREDICTION OF SURVIVAL OUTCOME WITH RADIOLOGICAL PHENOTYPES IN IDH-WILD TYPE LOWER GRADE GLIOMAS BASED ON MACHINE LEARNING
Authors: Sung Soo Ahn, Chae Jung Park, Yoon Seong Choi, Seung-Koo Lee
Journal: Neuro-Oncology (2018)

IDH-wild type lower grade gliomas are known to be similar to glioblastoma in terms of genetic alterations and prognostically heterogeneous. The purpose of this study was to investigate the prognostic value of imaging phenotypes using machine learning in IDH-wild type lower grade gliomas. Preoperative MRIs of 112 patients with histopathologically confirmed IDH-wild type grade II or III gliomas were retrospectively analyzed according to the Visually Accessible Rembrandt Images (VASARI) features set. A radiologic risk score (RRS) for overall survival (OS) and progression free survival (PFS) was produced by selected features and their regression coefficients from LASSO and Elastic net regression model with 100 times of repeated cross validation. Multivariable Cox analysis was performed including age, Karnofsky Performance score (KPS), grade, extent of resection and RRS. The added predictive value of RRS was calculated by comparing C-indices after bootstrapping between multivariable Cox models with and without RRS. For OS and PFS prediction, a Cox regression model comprising clinical features showed C-index of 0.741 and 0.737, respectively. When RRS derived from LASSO (RRS_L) was added to the model, C-index increased to 0.783 and 0.782 for OS and PFS prediction, respectively, without statistical significance. RRS_L was a strong predictor for both OS (HR 3.31) and PFS (HR 3.24). When RRS derived from Elastic net (RRS_E) was added to the model, the model achieved superior performance with C-index being 0.793 and 0.783 for OS and PFS prediction, respectively, with statistical significance (p < 0.05). RRS_E was an independent predictor for both OS (HR 2.62) and PFS (HR 2.80). RRS derived from MRI features using machine learning was independent predictors for survival in patients with IDH-wild type lower grade gliomas. Radiological phenotypes may have added prognostic value in patients with IDH-wild type lower grade gliomas.
The SAFFO study: Sex-related prognostic role and cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Authors: C. Lisanti, D. Basile, S.K. Garattini, A. Parnofiello, C. Corvaja, F. Cortiula, G. Pelizzari, M. Cattaneo, V.J. Andreotti, E. Bertoli, E. Ongaro, D. Iacono, L. Foltran, M. Casagrande, G. Miolo, G.G. Cardellino, G. Fasola, N. Pella, A. Buonadonna, F. Puglisi
Journal: Annals of Oncology (2019)
Clinical utility of precision immunoprofiling and monitoring of the tumour microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: Results from a phase II study for biomarker analysis (EPOC1702)
Authors: K. Kirita, E. Sugiyama, Y. Togashi, H. Udagawa, T. Irie, S. Iida, M. Nakamoto, S. Nomura, T. Ikeda, Y. Zenke, S. Matsumoto, K. Yoh, S. Niho, A. Sato, H. Nishikawa, K. Goto
Journal: Annals of Oncology (2019)
Abstract 19447: Glycogen Synthase Kinase-3a Regulates Fatty Acid Metabolism Through PPARa Phosphorylation That Underlies Lipotoxic Cardiomyopathy
Authors: Michinari Nakamura, Tong Liu, Peiyong Zhai, Junco S Warren, Bin Tian, Hong Li, Junichi Sadoshima
Journal: Circulation (2017)

Fatty acids are a major energy source for the heart. However, the mechanisms by which fatty acids signal to and balance the cellular metabolism and how disruption of this system induces lipotoxic c...
Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
Authors: T. Nagasaka, R. Inada, H. Ojima, S. Noura, H. Tanioka, Y. Munemoto, Y. Shimada, K. Ishibashi, Y. Shindo, Y. Kagawa, A. Tomibayashi, K. Okamoto, A. Tsuji, Y. Tsuji, S. Yamaguchi, A. Sawaki, H. Mishima, M. Shimokawa, M. Okajima, Y. Yamaguchi
Journal: Annals of Oncology (2019)
Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
Authors: A. Naing, T. Bauer, K.P. Papadopoulos, O. Rahma, F. Tsai, E. Garralda, J. Naidoo, S. Pai, M.K. Gibson, I. Rybkin, D. Wang, D.F. McDermott, A. Fasolo, M. de Miguel, M. Shaheen, Y. Jenkins, H. Kallender, S. Gogov, E. Kuriakose, M. Pishvaian
Journal: Annals of Oncology (2019)
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial
Authors: J.A. Chesney, I. Puzanov, F. Collichio, P. Singh, M. Milhem, J. Glaspy, O. Hamid, M.I. Ross, P. Friedlander, C. Garbe, T. Logan, A. Hauschild, C. Lebbe, M. Yi, A. Sharma, J.M. Mehnert
Journal: Annals of Oncology (2019)
Abstract 18700: Impact of Gender on Clinical Outcomes in Adults With In-hospital Cardiac Arrest
Authors: Jonah Garry, Robert Nguyen, Elinor Schoenfeld, Sam Parnia, Jignesh Patel
Journal: Circulation (2015)

Background: Despite numerous advances in the delivery of resuscitative care, in-hospital cardiac arrest (IHCA) continues to be associated with high morbidity and mortality. We sought to study the impact of gender on return of spontaneous circulation (ROSC) and survival to discharge in patients with IHCA. Methods: The study population included 255 consecutive patients who underwent ACLS-guided resuscitation from January 2012- December2013 for IHCA at an academic tertiary medical center. Baseline demographic, clinical, laboratory, and clinical outcome data were recorded. Outcomes of interest included presence of sustained ROSC (defined as ROSC &gt; 20 minutes) and survival to discharge. Results: Of the 255 patients studied, 96 (37.6%) were women and 159 (62.4%) were men. No difference in age, race, or ethnicity was noted between men and women. Women were shorter (160cm vs 174cm, p&lt;0.001) and had lower weight (78kg vs 89kg, p&lt;0.001), but had a trend towards higher body mass index (31.4 kg/m2 vs 29.4kg/m2, p=0.087). Women had lower rates of peripheral vascular disease (15.6% vs 27.0%, p=0.035) and hyperlipidemia (26.4% vs 41.6%, p=0.017). Rates of other comorbidities, including cardiovascular disease, chronic obstructive pulmonary disease, congestive heart failure, stroke, diabetes mellitus, chronic kidney disease, and hypertension were similar in men and women. Clinical presentation of IHCA, in particular, the initial rhythm, location of IHCA, duration of cardiopulmonary resuscitation, and laboratory results at the time of IHCA was similar in both men and women. With respect to outcomes, women were noted to have a trend toward lower rates of sustained ROSC (45.8% vs 57.9%, p=0.062) but no difference in survival to discharge (22.9% vs 27.0%, p=0.464). In multivariate analysis, gender was not an independent predictor of sustained ROSC or survival to discharge. Conclusion: Gender is not independently predictive of ROSC or survival to discharge in adults with IHCA.
TCT-80 Predictors of Residual Significant Mean Gradient After TAVR in Bicuspid Aortic Valve Stenosis: Insights From the BEAT International Collaborative Registry
Authors: Matteo Pagnesi, Antonio Mangieri, Didier Tchetche, Won-Keun Kim, Jan-Malte Sinning, Uri Landes, Ran Kornowski, Ole De Backer, Georg Nickenig, Alfonso Ielasi, Chiara De Biase, Lars Sondergaard, Federico De Marco, Matteo Montorfano, Mauro Chiarito, Giulio Stefanini, Patrizia Presbitero, Stefan Toggweiler, Corrado Tamburino, Sebastiano Immè, Giuseppe Tarantini, Horst Sievert, Ulrich Schäfer, Joerg Kempfert, Jochen Wöhrle, Francesco Gallo, Alessandra Laricchia, Azeem Latib, Francesco Giannini, Antonio Colombo
Journal: Journal of the American College of Cardiology (2019)
Quality of care outcomes among breast cancer patients treated with cancer care pathway regimens.
Authors: Santosh Gautam, Michael Jordan Fisch, Gosia Sylwestrzak, Michael Eleff, David Joseph Debono, ANN NGUYEN, John Barron
Journal: Journal of Clinical Oncology (2018)

e18827 Background: Cancer care pathways are used to enhance high quality cancer care. Those programs identify a set of optimal chemotherapy treatment regimens for various clinical scenarios based on their efficacy, toxicity and costs. The value of such regimens for breast cancer treatment has not been studied well. The objective of this study was to compare the quality of care outcomes among breast cancer patients treated with pathway regimens versus those who were not. Methods: Breast cancer patients receiving chemotherapy between Jan ’15 – Oct ‘16 were identified using administrative claims data as well as clinical data received from Anthem’s Cancer Care Quality Program. Cases with stage 0 disease, history of cancer, or prior exposure to chemotherapy were excluded. Patients receiving a pathway regimen (on-pathway cohort) were matched to those who did not (off-pathway cohort) using 1:1 propensity score matching. The two outcomes of interest were: rate of chemotherapy-related avoidable hospitalizations (defined as at least one inpatient visit for chemotherapy-related adverse events such as neutropenia, anemia, fever, nausea, and fatigue during the post-index 30 days), and need for supportive drugs (defined as having at least one claim for granulocyte colony stimulating factor or erythropoiesis-stimulating agent during the post-index 6 months) Results: There were 995 patients in each cohort after matching. Patients in both cohorts had similar age distribution (median age 52 off- vs. 53 on-pathway), mostly present with Stage II disease (49.4% off- vs. 49.8% on-pathway), and nearly one-third had a hormone receptor positive cancer (28.2% off- vs. 30.1% on-pathway). The cohorts had similar rates of chemotherapy-related avoidable hospitalization (2.4% off- vs. 2.5% on-pathway; odds ratio 1.04; p = 0.88) but a lower rate of needs for supportive drugs (82.4% off- vs. 74.4% on-pathway; odds ratio = 0.52; p < .0001). Conclusions: Pathway regimens for breast cancer are associated with lower toxicity as evidenced by reduced needs for supportive drugs and they do not change the rate of chemotherapy-related avoidable hospitalizations.
Abstract 18919: Outcomes of Catheter Ablation for Atrial Fibrillation in the Elderly- Data From the Largest Inpatient Registry(2011-2014)
Authors: Kanishk Agnihotri, Parshva Patel, Kriti Sharma, Subir Bhatia, Ghanshyam Shantha, Nilay Patel, Anil K Jonnalagadda, Ekta Aneja, Abhishek Kumar, Krishna Kancherla, Hakan Paydak, Abhishek Deshmukh
Journal: Circulation (2017)

Introduction: Atrial Fibrillation (AF) ablation has made tremendous progress with respect to innovation, efficacy and safety. Contemporary large scale data on outcomes of catheter ablation for AF i...
Case 31-2019: A 45-Year-Old Woman with Headache and Somnolence
Authors: Allan R. Tunkel, Elinor L. Baron, Karen A. Buch, Francisco M. Marty, Maria Martinez-Lage
Journal: New England Journal of Medicine (2019)

A 45-year-old woman with multiple sclerosis who had been receiving multiple immunosuppressive therapies was admitted to the hospital because of headache and somnolence. Analysis of the cerebrospinal fluid revealed an elevated opening pressure, mononuclear pleocytosis, a normal glucose level, and an elevated protein level. A diagnostic test result was received.
GPs warn over scoring system for calling ambulances for patients
Authors: Elisabeth Mahase
Journal: BMJ (2019)

A scoring system designed to identify deteriorating patients in secondary care is “creeping” into primary care, despite a lack of evidence for its use in community settings, GPs have warned.

GPs are being asked to provide a score when calling for an ambulance for a patient and are concerned that this is being used to decide how urgently their patient needs an ambulance, over-riding their clinical judgment.

The issue was raised at the Royal College for General Practitioners’ council meeting on 20 September, where members voiced concern about the lack of evidence for using NEWS2, an updated version of the National Early Warning Score, in primary care.

The scoring system is used to identify and respond to patients at risk of deteriorating. It is based on six physiological measures: respiratory rate, …
Concerns Regarding a Meta-analysis Comparing Psychotherapy With Medications for Posttraumatic Stress Disorder
Authors: Jeffrey Sonis, Joan M. Cook
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Critical Role of Endogenous ADP Via P2Y12 Receptor in Maintenance of αIibβ3 Activation.
Authors: Tsuyoshi Kamae, Masamichi Shiraga, Hirokazu Kashiwagi, Hisashi Kato, Seiji Tadokoro, Yoshiyuki Kurata, Yoshiaki Tomiyama, Yuzuru Kanakura
Journal: Blood (2005)
Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
Authors: R. Govindan, M.G. Fakih, T.J. Price, G.S. Falchook, J. Desai, J.C. Kuo, J.H. Strickler, J.C. Krauss, B.T. Li, C.S. Denlinger, G. Durm, J. Ngang, H. Henary, G. Ngarmchamnanrith, E. Rasmussen, P.K. Morrow, D.S. Hong
Journal: Annals of Oncology (2019)
Aptamer-mediated exosomes detection for early breast cancer identification
Authors: C. Quintavalle, C.L. Esposito, F. Ingenito, A. Affinito, G. Roscigno, I. Scognamiglio, S. Nuzzo, S. Catuogno, R. Thomas, G. Condorelli
Journal: Annals of Oncology (2019)
EURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma
Authors: P. Reichardt, K Sundby Hall, R. Bertulli, S.S. Bielack, A. Comandone, G. Egerer, A. Hansmeier, E. Palmerini, S. Smeland, S. Ferrari
Journal: Annals of Oncology (2019)
Improving the quality of surgery for gastric cancer—Are surgeons aware of the relevant quality indicators?
Authors: L. K. Helyer, C. O Brien, N. G. Coburn, C. J. Swallow
Journal: Journal of Clinical Oncology (2006)

4048 Background: Gastric cancer survival in the West is inferior to that achieved in Asian centers. While differences in tumor biology may play a role, poor quality surgery contributes to understaging. In our evaluation, adequate lymph node (LN) assessment (≥15) was achieved in only one third of patients and independently predicted survival across Surveillance, Epidemiology and End Results (SEER) regions (ASCO 2005, Abstract # 4004). The standard proximal margin of resection is recommended to be ≥5 cm; revision based on intraoperative frozen section is of benefit. We hypothesize that the majority of surgeons performing gastric cancer surgery in a North American setting are unaware of the recommended standards. Methods: Using the Ontario College of Physicians and Surgeons registry, surgeons who potentially include gastric cancer surgery in their scope of practice were identified. A questionnaire was mailed to 559, 55% responded. 203surgeons reported managing gastric cancer. Results were evaluated by chi-square and logistic regression; p&lt;0.05 was considered significant. Results: 86% of respondents were male; 59% in urban non-academic practice, and 30% in academic. 42% of surgeons operate on 2–5 cases/yr and 18 % on &gt;5. One third of surgeons identified ≤ 4 cm to be the desired proximal margin. Frozen section is used by 52% to evaluate proximal margin status. 20% were unsure of the number of LN needed to accuratly stage, the median number reported by the remainder was 10 (range 0 - 30). 99% refer for adjuvant therapy. This was less likely for patients in poor medical condition, poor nutritional status, or age &gt;70 years. Young patients, those with bulky LN or positive margins were more likely to be referred. Overall, only 16 of 203identified the need for both a ≥5 cm proximal margin and ≥15LN; this was too small a group to analyze for demographic associations. Surgeons who do &gt;5 gastric resections/yr were more likely to report performing a D2 resection (p = 0.008). Conclusions: The majority of surgeons operating on gastric cancer in Ontario did not identify standard quality indicators of gastric cancer surgery. A continuing medical education program should be designed to address the knowledge gap, aiming to improve the quality of surgery and outcome of multidisciplinary management. No significant financial relationships to disclose.
Abstract 14796: Endotoxin Induced Cardiac Metabolic Shift is Controlled Through the Regulation of Fatty Acid Oxidation by a Beta-3 Adrenergic Receptor
Authors: Satoshi Kawaguchi, Motoi Okada, Daisuke Koga, Satoshi Fujita, Naoyuki Hasebe
Journal: Circulation (2018)

Background: The cardiac metabolic shift has been observed in failing heart for starvation of the energy. CPT1 is an enzyme which takes a fatty acid into mitochondria and dysfunction of CPT1 reduces...
Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis
Authors: Anh-Thu N. Lam, Melis A. Aksit, Briana Vecchio-Pagan, Celeste A. Shelton, Derek L. Osorio, Arianna F. Anzmann, Loyal A. Goff, David C. Whitcomb, Scott M. Blackman, Garry R. Cutting
Journal: Journal of Clinical Investigation (2019)

Diabetes is a common complication of cystic fibrosis (CF) that affects approximately 20% of adolescents and 40%-50% of adults with CF. The age at onset of CF-related diabetes (CFRD) (marked by clinical diagnosis and treatment initiation) is an important measure of the disease process. DNA variants associated with age at onset of CFRD reside in and near SLC26A9. Deep sequencing of the SLC26A9 gene in 762 individuals with CF revealed that 2 common DNA haplotypes formed by the risk variants account for the association with diabetes. Single-cell RNA sequencing (scRNA-Seq) indicated that SLC26A9 is predominantly expressed in pancreatic ductal cells and frequently coexpressed with CF transmembrane conductance regulator (CFTR) along with transcription factors that have binding sites 5' of SLC26A9. These findings were replicated upon reanalysis of scRNA-Seq data from 4 independent studies. DNA fragments derived from the 5' region of SLC26A9-bearing variants from the low-risk haplotype generated 12%-20% higher levels of expression in PANC-1 and CFPAC-1 cells compared with the high- risk haplotype. Taken together, our findings indicate that an increase in SLC26A9 expression in ductal cells of the pancreas delays the age at onset of diabetes, suggesting a CFTR-agnostic treatment for a major complication of CF.